Teva Pharma's Key Branded Drugs Fuel Strong Revenue Growth, Lifts Full-Year Profit Outlook
1. TEVA's Q3 revenue was $4.48 billion, exceeding expectations. 2. Austedo sales surged 38% to $618 million, raising its revenue outlook. 3. TEVA raised its 2025 adjusted earnings forecast to $2.55-$2.65 per share. 4. Overall sales guidance for 2025 narrowed, reflecting strong performance. 5. Stock price increased significantly by 18.23%, indicating positive market response.